Surgery Partners (SGRY) Lowered to Sell at ValuEngine

ValuEngine lowered shares of Surgery Partners (NASDAQ:SGRY) from a hold rating to a sell rating in a research report report published on Friday morning.

Other research analysts have also recently issued reports about the stock. Bank of America decreased their target price on shares of Surgery Partners from $23.00 to $19.00 and set a buy rating for the company in a report on Monday, October 9th. Benchmark set a $19.00 target price on shares of Surgery Partners and gave the stock a buy rating in a report on Tuesday, January 30th. Jefferies Group decreased their target price on shares of Surgery Partners from $16.00 to $13.00 and set a buy rating for the company in a report on Wednesday, November 1st. Royal Bank of Canada reiterated a buy rating and issued a $18.00 target price on shares of Surgery Partners in a report on Sunday, November 12th. Finally, Zacks Investment Research upgraded shares of Surgery Partners from a sell rating to a hold rating in a report on Saturday, January 13th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. Surgery Partners presently has a consensus rating of Hold and an average target price of $17.86.

Surgery Partners (SGRY) opened at $14.65 on Friday. Surgery Partners has a fifty-two week low of $7.10 and a fifty-two week high of $24.05. The company has a market cap of $714.47, a PE ratio of -31.85 and a beta of 2.47. The company has a quick ratio of 1.92, a current ratio of 2.09 and a debt-to-equity ratio of 1.56.

Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Wednesday, November 8th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. Surgery Partners had a negative net margin of 0.33% and a positive return on equity of 1.03%. sell-side analysts predict that Surgery Partners will post -0.16 EPS for the current year.

Surgery Partners announced that its board has initiated a share repurchase program on Friday, December 15th that authorizes the company to repurchase $50.00 million in shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Aperio Group LLC purchased a new stake in shares of Surgery Partners in the fourth quarter worth approximately $173,000. Phoenix Investment Adviser LLC lifted its position in shares of Surgery Partners by 32.5% in the fourth quarter. Phoenix Investment Adviser LLC now owns 95,290 shares of the company’s stock worth $1,153,000 after purchasing an additional 23,400 shares in the last quarter. Sterling Capital Management LLC purchased a new stake in shares of Surgery Partners in the third quarter worth approximately $210,000. Bain Capital Investors LLC purchased a new stake in shares of Surgery Partners in the third quarter worth approximately $273,816,000. Finally, Royce & Associates LP lifted its position in shares of Surgery Partners by 160.0% in the third quarter. Royce & Associates LP now owns 681,582 shares of the company’s stock worth $7,054,000 after purchasing an additional 419,457 shares in the last quarter. 94.03% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/02/05/surgery-partners-sgry-lowered-to-sell-at-valuengine.html.

Surgery Partners Company Profile

Surgery Partners, Inc is a healthcare services company. The Company operates in three lines of business across the United States: Surgical Facility Services, Ancillary Services and Optical Services. The Company’s Surgical Facility Services segment consists of the operation of ambulatory surgery centers (ASCs) and surgical hospitals, which include its anesthesia services.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Surgery Partners (NASDAQ:SGRY)

Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit